Ascl1 and OTP tumour expressions are associated with disease-free survival in lung atypical carcinoids.
Ascl1
Ki-67 index
OTP
atypical carcinoids
lung
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
11
01
2023
received:
21
10
2022
accepted:
28
01
2023
medline:
4
4
2023
pubmed:
1
2
2023
entrez:
31
1
2023
Statut:
ppublish
Résumé
According to World Health Organization guidelines, atypical carcinoids (ACs) are well-differentiated lung neuroendocrine tumours with 2-10 mitoses/2 mm
Substances chimiques
Ki-67 Antigen
0
ASCL1 protein, human
0
Basic Helix-Loop-Helix Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
870-884Subventions
Organisme : Italian Ministry of Health
ID : ERP-2017-23671129
Organisme : Integrative Molecular Analysis of Pure and Combined Lung Large Cell Neuroendocrine Carcinoma (LCNEC)
Organisme : Italian Ministry of Health with Ricerca Corrente
Organisme : FIRC-AIRC
Informations de copyright
© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
World HO. Thoracic tumors. Lyon, France. Geneva, Switzerland: International Agency for Research on Cancer. Print copies are distributed by WHO Press, World Health Organization, 2021 xiii, 565 pages: illustrations (color, black and white).
Baudin E, Hayes AR, Scoazec JY et al. Unmet medical needs in pulmonary neuroendocrine (carcinoid) neoplasms. Neuroendocrinology 2019; 108; 7-17.
Huang Y, Yang X, Lu T et al. Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population-based study. Cancer Med. 2018; 7; 2434-2441.
Caplin ME, Baudin E, Ferolla P et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 2015; 26; 1604-1620.
Jiang SX, Kameya T, Asamura H et al. Hash1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod. Pathol. 2004; 17; 222-229.
Moonen L, Derks J, Dingemans AM, Speel EJ. Orthopedia homeobox (otp) in pulmonary neuroendocrine tumors: the diagnostic value and possible molecular interactions. Cancers (Basel) 2019; 1508; 11.
Marchio C, Gatti G, Massa F et al. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch. 2017; 471; 713-720.
Nagtegaal ID, Odze RD, Klimstra D et al. The 2019 who classification of tumours of the digestive system. Histopathology 2020; 76; 182-188.
Volante M, Brizzi MP, Faggiano A et al. Somatostatin receptor type 2a immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod. Pathol. 2007; 20; 1172-1182.
Rindi G, Klersy C, Inzani F et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr. Relat. Cancer 2014; 21; 1-16.
Prinzi N, Rossi RE, Proto C et al. Recent advances in the management of typical and atypical lung carcinoids. Clin. Lung Cancer 2021; 22; 161-169.
Castro DS, Martynoga B, Parras C et al. A novel function of the proneural factor ascl1 in progenitor proliferation identified by genome-wide characterization of its targets. Genes Dev. 2011; 25; 930-945.
Altree-Tacha D, Tyrrell J, Li F. Mash1 is highly specific for neuroendocrine carcinomas: an immunohistochemical evaluation on normal and various neoplastic tissues. Arch. Pathol. Lab. Med. 2017; 141; 288-292.
Ye B, Cappel J, Findeis-Hosey J et al. Hash1 is a specific immunohistochemical marker for lung neuroendocrine tumors. Hum. Pathol. 2016; 48; 142-147.
Laddha SV, da Silva EM, Robzyk K et al. Integrative genomic characterization identifies molecular subtypes of lung carcinoids. Cancer Res. 2019; 79; 4339-4347.
Borromeo MD, Savage TK, Kollipara RK et al. Ascl1 and neurod1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 2016; 16; 1259-1272.
Baine MK, Hsieh MS, Lai WV et al. Sclc subtypes defined by ascl1, neurod1, pou2f3, and yap1: a comprehensive immunohistochemical and histopathologic characterization. J. Thorac. Oncol. 2020; 15; 1823-1835.
Nonaka D, Papaxoinis G, Mansoor W. Diagnostic utility of orthopedia homeobox (otp) in pulmonary carcinoid tumors. Am. J. Surg. Pathol. 2016; 40; 738-744.
Alcala N, Leblay N, Gabriel AAG et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat. Commun. 2019; 10; 3407.
Swarts DR, Henfling ME, Van Neste L et al. Cd44 and otp are strong prognostic markers for pulmonary carcinoids. Clin. Cancer Res. 2013; 19; 2197-2207.
Papaxoinis G, Nonaka D, O'Brien C, Sanderson B, Krysiak P, Mansoor W. Prognostic significance of cd44 and orthopedia homeobox protein (otp) expression in pulmonary carcinoid tumours. Endocr. Pathol. 2017; 28; 60-70.
Derks JL, Rijnsburger N, Hermans BCM et al. Clinical-pathologic challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice. J. Thorac. Oncol. 2021; 16; 1632-1646.
Clay V, Papaxoinis G, Sanderson B et al. Evaluation of diagnostic and prognostic significance of ki-67 index in pulmonary carcinoid tumours. Clin. Transl. Oncol. 2017; 19; 579-586.
Oka N, Kasajima A, Konukiewitz B et al. Classification and prognostic stratification of bronchopulmonary neuroendocrine neoplasms. Neuroendocrinology 2020; 110; 393-403.
Dermawan JKT, Farver CF. The role of histologic grading and ki-67 index in predicting outcomes in pulmonary carcinoid tumors. Am. J. Surg. Pathol. 2020; 44; 224-231.
Centonze G, Maisonneuve P, Simbolo M et al. Lung carcinoid tumors: Histology and ki-67, the eternal rivalry. Histopathology 2022; 82; 324-339.
Hermans BCM, Derks JL, Moonen L et al. Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: Illustrated by a case series and review of the literature. Lung Cancer 2020; 150; 152-158.
IARC. World Health Organization classification of tumours 1. Digestive system tumours. 1.1 ed. Lyon: IARC, 2019; 635.